Taken together these data suggest that SMC in general, and the PDGFD/PDGFRB signaling pathway, do not mediate CAD risk through altering the extent of disease but rather through regulation of disease features that regulate vascular stability. This evidence concerns the gene PDGFD and coronary artery disorder.